LivaNova PLC (NASDAQ:LIVN) Shares Sold by MetLife Investment Management LLC

MetLife Investment Management LLC lessened its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 0.7% in the 3rd quarter, Holdings Channel reports. The firm owned 58,619 shares of the company’s stock after selling 433 shares during the period. MetLife Investment Management LLC’s holdings in LivaNova were worth $3,080,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Arizona State Retirement System raised its position in shares of LivaNova by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock worth $828,000 after purchasing an additional 299 shares during the last quarter. Atria Investments Inc raised its position in shares of LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after purchasing an additional 331 shares during the last quarter. Fifth Third Bancorp raised its position in shares of LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares during the last quarter. Hexagon Capital Partners LLC raised its position in shares of LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after purchasing an additional 370 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its position in shares of LivaNova by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after purchasing an additional 425 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Performance

LivaNova stock opened at $51.62 on Wednesday. The firm has a 50 day simple moving average of $52.29 and a 200-day simple moving average of $51.95. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.47. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of 122.90 and a beta of 0.98.

Analyst Upgrades and Downgrades

LIVN has been the subject of several research reports. Robert W. Baird upped their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 16th. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Mizuho dropped their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Finally, The Goldman Sachs Group initiated coverage on shares of LivaNova in a research note on Friday, October 4th. They set a “buy” rating and a $65.00 price objective for the company. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, LivaNova presently has a consensus rating of “Buy” and a consensus price target of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.